A Phase I Study of MRX-2843 in Adolescents and Young Adults with Recurrent or Persistent Acute Leukemias

Share

Full Title

An Open-Label Evaluation Phase 1 Trial of the Safety and Pharmacokinetics of MRX-2843 in Adolescents and Adults With Relapsed/Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Mixed Phenotype Acute Leukemia

Purpose

The purpose of this study is to find the highest dose of the investigational drug MRX-2843 that can be given safely in adolescents and young adults with acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), or mixed phenotype acute leukemia (MPAL) that has returned or persisted despite treatment. MRX-2843 blocks two proteins (MerTK and FLT3) that are commonly increased in people with these types of cancer. By blocking these proteins, MRX-2843 may be effective against leukemia. MRX-2843 is a capsule that is taken orally (by mouth).

Eligibility

To be eligible for this study, patients must meet several requirements, including:

  • Participants must have AML, ALL, or MPAL that has come back or continued to grow despite treatment.
  • This study is for people age 12 and older.

For more information about this study or to ask about eligibility, please call 833-MSK-KIDS.

Protocol

22-080

Phase

I

Disease Status

Relapsed or Refractory

Investigator

Co-Investigators